ArticleScientific reports2026
FA-DeepMSM: a few-shot adapted interpretable multimodal survival model for improved prognostic prediction in glioblastoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Survival prediction in IDH-wildtype glioblastoma is an inherently time-dependent challenge that remains clinically critical, yet limited by inter-institutional heterogeneity and insufficient labeled data. Existing deep learning prognostic models often overfit to high-dimensional imaging features and fail to generalize across clinical settings. To address these limitations, we developed FA-DeepMSM (Few-shot Adapted Deep Multimodal Survival Model), which integrates self-supervised MRI features with clinical and molecular variables within a few-shot learning framework. High-dimensional MRI embeddings were extracted from 1,359 adult-type diffuse glioma patients using large multi-institutional datasets combining in-house and publicly available cohorts with survival data through a pretrained DINOv2 vision transformer and fused with structured tabular data in a transformer-based survival architecture. The model was fine-tuned under 0-, 5-, 10-, 20-, and 40-shot settings using an external glioblastoma cohort from UPenn (n = 452). Few-shot adaptation significantly improved generalization, increasing the average time-dependent C-index from 0.643 (0-shot) to 0.680 (40-shot). To enhance interpretability, FA-DeepMSM incorporates a time-resolved explainability module based on permutation analysis, enabling variable-level risk attribution across survival timepoints (3, 6, 12, 18, and 24 months). Early prognosis was primarily driven by extent of resection, whereas later survival phases were more influenced by MGMT promoter methylation and image-derived features. By addressing data scarcity, cross-modal misalignment, and limited interpretability, FA-DeepMSM establishes a clinically scalable and explainable paradigm for outcome prediction in neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.